Patents by Inventor Christopher Edlin
Christopher Edlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7943616Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.Type: GrantFiled: November 23, 2004Date of Patent: May 17, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N. A. Bezard, Chantal Carrez
-
Publication number: 20080058369Abstract: The invention provides N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide, whose formula is , or a salt thereof, such as the monohydrochloride salt thereof. The invention also provides the use of the compound or salt as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, or rhinitis (e.g. allergic and/or non-allergic rhinitis).Type: ApplicationFiled: July 31, 2007Publication date: March 6, 2008Inventors: David Allen, Rodger Barnett, Reshma Chudasama, Caroline Day, Christopher Edlin, Leanda Kindon
-
Publication number: 20080021058Abstract: The invention provides a compound of formula (I) or a salt thereof: wherein W is Ar, —CR4R5Ar or a group (y) or (y1), wherein Ar is (x) or (z): R1 is C1-4alkyl, C1-3fluoroalkyl or —CH2CH2OH. R2 is C2-6alkyl, C3-6cycloalkyl or —(CH2)n4-C3-6cycloalkyl; and R3 is optionally substituted C3-8cycloalkyl, optionally substituted mono-unsaturated-C5-7cycloalkenyl, an optionally substituted heterocyclic group (aa), (bb) or (cc) (in which Y is O, S, SO2, or NR10), or a bicyclic group (ee): These compounds are PDE4 inhibitors.Type: ApplicationFiled: March 15, 2005Publication date: January 24, 2008Inventors: David Allen, Diane Coe, Caroline Cook, Michael Dowle, Christopher Edlin, Julie Hamblin, Martin Johnson, Paul Jones, Mika Lindvall, Charlotte Mitchell, Alison Redgrave, Naimisha Trivedi
-
Publication number: 20070280971Abstract: The invention provides 4-{[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, which is the compound of formula (I): or a salt thereof.Type: ApplicationFiled: March 15, 2005Publication date: December 6, 2007Inventors: Siegfried Christensen, Caroline Cook, Christopher Edlin, Martin Johnson, Paul Jones, Mika Lindvall, Amyn Sayani, Naimisha Trivedi, Lionel Trottet
-
Patent number: 7259154Abstract: Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.Type: GrantFiled: December 23, 2003Date of Patent: August 21, 2007Assignee: Aventis Pharmaceuticals Inc.Inventors: Paul Joseph Cox, Tahir Nadeem Majid, Stephanie Daniele Deprets, Shelley Amendola, Iain McFarlane McLay, Christopher Edlin, David John Aldous, Brian Pedgrift, Frank Halley, Michael Edwards, Bernard Baudoin
-
Publication number: 20070191426Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type IV (PDE4) and are of use in the treatment of inflammatory and/or allergic diseases.Type: ApplicationFiled: September 27, 2004Publication date: August 16, 2007Inventors: Christopher Edlin, Colin Eldred, Christopher Lunniss, Alison Redgrave, John Robinson, Michael Woodrow
-
Publication number: 20070167485Abstract: The invention relates to a compound of formula (I) or a salt thereof: wherein: R1 is Et, n-Pr, i-Pr, C2fluoroalkyl, or —CH2CH2OH; R2 is H, Me, Et, n-Pr, i-Pr, C1-2fluoroalkyl, cyclopropyl or (cyclopropyl)methyl-; and NHR3 has the sub-formula (nhr3): wherein R3a is methyl or ethyl; R3b is H, methyl or ethyl; R3c is H, methyl or ethyl, R3d is H, methyl or ethyl, and R3e is H or methyl, provided that: (a) R3b is methyl or ethyl; and/or (b) R3c and R3d are independently methyl or ethyl; and provided that: (c) when R3c is ethyl and/or when R3d is ethyl and/or when R3e is methyl, then: R3a is methyl and/or R3b is hydrogen or methyl. These compounds are PDE4 inhibitors.Type: ApplicationFiled: March 15, 2005Publication date: July 19, 2007Inventors: Diane Coe, Caroline Cook, Anthony Cooper, Christopher Edlin, Julie Hamblin, Martin Johnson, Paul Jones, Mika Lindvall, Charlotte Mitchell, Alison Redgrave, John Robinson
-
Publication number: 20060014756Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.Type: ApplicationFiled: January 4, 2005Publication date: January 19, 2006Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Michael Edwards, Paul Cox, Shelley Amendola, Stephanie Deprets, Timothy Gillespy, Christopher Edlin, Andrew Morley, Charles Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir Majid, John Reader, Lloyd Payne, Nawaz Khan, Michael Cherry
-
Publication number: 20050267304Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.Type: ApplicationFiled: November 23, 2004Publication date: December 1, 2005Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Paul Cox, Tahir Majid, Justine Lai, Andrew Morley, Shelley Amendola, Stephanie Deprets, Christopher Edlin, Charles Gardner, Dorothea Kominos, Brian Pedgrift, Frank Halley, Timothy Gillespy, Michael Edwards, Francois Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel Bezard, Chantal Carrez
-
Patent number: 6897207Abstract: The invention is directed to physiologically active compounds of general formula (I): and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.Type: GrantFiled: June 21, 2002Date of Patent: May 24, 2005Assignee: Aventis Pharmaceuticals Inc.Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N. A. Bezard, Chantal Carrez
-
Patent number: 6770643Abstract: The invention is directed to compositions containing physiologically active compounds of general formula (I): wherein R1 is aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, —Z1R8, —C(═O)—NY3Y4, —CO2R8, —NY3Y4, —N(R6)—C(═O)—R7, —N(R6)—C(═O)—NY3Y4, —N(R6)—C(═O)—OR7, —N(R6)—SO2—R7, —N(R6)—SO2—NY3Y4 and one or more halogen a toms ; R3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, —C(═O)—OR5 or —C(═O)—NY3Y; and X1 represents N, CH, C-halo, C—CN, C—R7, C—NY3Y4, C—OH, C—Z2R7, C—C(═O)—OR5, C—C(═O)—NY3Y4, C—N(R8)—C(═O)—R7, C—SO2—NY3Y4, C—N(R8)—SO2—R7, C-alkenyl, C-Type: GrantFiled: June 24, 2002Date of Patent: August 3, 2004Assignee: Aventis Pharma LimitedInventors: Paul J Cox, Tahir N. Majid, Justine Y. Q. Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin
-
Publication number: 20040142947Abstract: Compounds of the formula 1Type: ApplicationFiled: December 23, 2003Publication date: July 22, 2004Applicant: Aventis Pharmaceuticals, Inc.Inventors: Paul Joseph Cox, Tahir Nadeem Majid, Stephanie Daniele Deprets, Shelley Amendola, Iain McFarlane McLay, Christopher Edlin, David John Aldous, Brian Pedgrift, Frank Halley, Michael Edwards, Bernard Baudoin
-
Publication number: 20040053931Abstract: The invention is directed to physiologically active compounds of general formula (I):— 1Type: ApplicationFiled: June 21, 2002Publication date: March 18, 2004Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N.A. Bezard, Chantal Carrez
-
Publication number: 20040009983Abstract: The invention is directed to compositions containing physiologically active compounds of general formula (I): 1Type: ApplicationFiled: June 24, 2002Publication date: January 15, 2004Inventors: Paul J. Cox, Tahir N. Majid, Justine Y.Q. Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin